Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors

NCT07182435 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor Malignancies

Interventions

BIOLOGICAL: personalized neoantigen mRNA tumor vaccine

Sponsor

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center